{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abatacept+infusion&page=2", "query": { "intervention": "abatacept infusion", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abatacept+infusion&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T02:03:37.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00035529", "title": "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "BMS 188667 (Abatacept)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2010-12-06", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035529" }, { "nct_id": "NCT00162279", "title": "The Study of Abatacept in Combination With Etanercept", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2000-10", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2010-12-06", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 35, "location_summary": "Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00162279" }, { "nct_id": "NCT05289167", "title": "Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft-versus-host Disease" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "14 Years to 100 Years" }, "enrollment_count": 74, "start_date": "2022-03-13", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05289167" }, { "nct_id": "NCT00578448", "title": "Belatacept Pharmacokinetic Trial in Renal Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2008-03", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 2, "location_summary": "Springfield, Massachusetts • Detriot, Michigan", "locations": [ { "city": "Springfield", "state": "Massachusetts" }, { "city": "Detriot", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578448" }, { "nct_id": "NCT02137239", "title": "Regimen Optimization Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "mycophenolate mofetil(MMF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "Everolimus(EVL)", "type": "DRUG" }, { "name": "Tacrolimus(TAC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 58, "start_date": "2015-12-31", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 17, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 14 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137239" }, { "nct_id": "NCT00455013", "title": "A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Disorder Related to Renal Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 93, "start_date": "2007-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 11, "location_summary": "San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455013" }, { "nct_id": "NCT00402168", "title": "A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2007-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-01-05", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402168" }, { "nct_id": "NCT04955366", "title": "Abatacept Conversion in Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplant Recipient" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2021-09-22", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955366" }, { "nct_id": "NCT03086343", "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2017-05-09", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 44, "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086343" }, { "nct_id": "NCT04827979", "title": "Daratumumab and Belatacept for Desensitization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Highly Sensitized Prospective Kidney Transplant Recipients" ], "interventions": [ { "name": "daratumumab", "type": "BIOLOGICAL" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "Bone marrow aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2021-11-01", "completion_date": "2026-04-02", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-29T02:03:37.365Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04827979" } ] }